Eli Lilly and Co (LLY.N)
31 Jul 2015
July 23 - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.
DUBLIN, July 16 - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management.
* British biotech firm immunocore says secures $320 million in Europe's largest private life sciences financing
WASHINGTON - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.
July 7 - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a preliminary review by the U.S. Food and Drug Administration.
* Indexes up: Dow 0.06 pct, S&P 0.13 pct, Nasdaq 0.14 pct (Updates to early afternoon)
where assigned, and hit the newskey (F9 on Reuters terminals)
Thomson Reuters April 27, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events.
- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States.
April 23 - Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥6,240||+138.00|
|Johnson & Johnson (JNJ.N)||$100.21||+0.37|
|Pfizer Inc. (PFE.N)||$36.06||+0.33|
|Novartis AG (NOVN.VX)||CHF100.40||+0.40|
|Merck & Co., Inc. (MRK.N)||$58.96||+0.44|
|Abbott Laboratories (ABT.N)||$50.69||-0.08|
|Sanofi SA (SASY.PA)||€97.97||+0.20|
|AstraZeneca plc (AZN.L)||4,320.00p||+0.50|
|GlaxoSmithKline plc (GSK.L)||1,396.00p||+7.00|
|Bristol-Myers Squibb Co (BMY.N)||$65.64||+1.18|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : Stock Traders Daily
Provider : Pechala's Reports
Eli Lilly and Co: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Validea Guru Analysis Report for LLY. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Provider : Validea
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.